Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Curis Inc (CRIS)

Curis Inc (CRIS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 52,129
  • Shares Outstanding, K 33,203
  • Annual Sales, $ 10,430 K
  • Annual Income, $ -32,580 K
  • 60-Month Beta 2.42
  • Price/Sales 5.86
  • Price/Cash Flow N/A
  • Price/Book N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.29 +21.71%
on 11/12/19
2.02 -22.25%
on 11/26/19
-0.22 (-12.29%)
since 11/06/19
3-Month
1.29 +21.71%
on 11/12/19
2.60 -39.62%
on 11/04/19
-0.31 (-16.49%)
since 09/06/19
52-Week
0.60 +161.67%
on 12/11/18
2.90 -45.86%
on 07/17/19
+0.82 (+109.33%)
since 12/06/18

Most Recent Stories

More News
Curis Provides First-Ever Demonstration that Targeting IRAK4 in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma Results in Anti-Cancer Activity in Ongoing Phase 1 Study

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced updated preliminary data from its ongoing Phase 1...

CRIS : 1.57 (-14.67%)
Curis Announces Positive Safety, Tolerability and Pharmacokinetic Data in Ongoing Phase 1 Study of Fimepinostat in Combination with Venetoclax

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced preliminary tolerability and PK data from its ongoing...

CRIS : 1.57 (-14.67%)
Curis to Present at 31st Annual Piper Jaffray Healthcare Conference

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, Chief Executive Officer of Curis,...

CRIS : 1.57 (-14.67%)
Curis Abstracts for Fimepinostat and CA-4948 Accepted for Presentation at the 61st Annual Meeting of the American Society of Hematology

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that abstracts for both fimepinostat and CA-4948 were...

CRIS : 1.57 (-14.67%)
Curis: 3Q Earnings Snapshot

LEXINGTON, Mass. (AP) _ Curis Inc. (CRIS) on Tuesday reported a loss of $6.4 million in its third quarter.

CRIS : 1.57 (-14.67%)
Curis Reports Third Quarter 2019 Financial Results

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the third quarter ended September...

CRIS : 1.57 (-14.67%)
/U P D A T E D -- Curis, Inc./

In a release issued under the same headline on October 29th by Curis, Inc., please note that in the first and second paragraphs of the release, financial results will be reported before Nasdaq market open,...

CRIS : 1.57 (-14.67%)
Curis to Release Third Quarter Financial Results and Hold Conference Call on November 5, 2019

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its third quarter financial...

CRIS : 1.57 (-14.67%)
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on October 1, 2019, the independent Compensation...

CRIS : 1.57 (-14.67%)
Patients Turn to Assistance Programs for Aid in the Fight Against Chronic Diseases

With the advancement of the cancer therapy market, new forms of treatment are now being studied and manufactured. Additionally, demand is expected to keep growing for currently effective treatments. Not...

CRIS : 1.57 (-14.67%)
IMMU : 20.59 (+11.30%)
ZIOP : 5.16 (+1.38%)
ONPH : 0.0250 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Trade CRIS with:

Business Summary

Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis' product development involves the use of small molecules or proteins to modulate...

See More

Key Turning Points

2nd Resistance Point 2.10
1st Resistance Point 1.84
Last Price 1.57
1st Support Level 1.36
2nd Support Level 1.14

See More

52-Week High 2.90
Fibonacci 61.8% 2.02
Fibonacci 50% 1.75
Last Price 1.57
Fibonacci 38.2% 1.48
52-Week Low 0.60

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar